The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Abstract
OBJECTIVE: The association of hyperglycemia and hypercholesterolemia with use of atypical antipsychotics has been documented in case reports and uncontrolled studies. The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial. METHOD: One hundred fifty-seven patients with schizophrenia or schizoaffective disorder who were inpatients at four hospitals were originally included in the study. The 14-week trial consisted of an 8-week fixed-dose period and a 6-week variable-dose period. Planned assessments included fasting glucose and cholesterol, which were collected at baseline and at the end of the 8-week period and the following 6-week period. RESULTS: One hundred eight of the 157 patients provided blood samples at baseline and at least at one point after random assignment to clozapine, olanzapine, risperidone, or haloperidol during the treatment trial. Seven of these patients had diabetes; their glucose levels were >125 mg/dl at baseline. Data from 101 patients were used for statistical analyses. During the initial 8-week period there was an overall significant increase in mean glucose levels. There were significant increases in glucose levels at the end of the 8-week fixed-dose period for patients given clozapine (N=27) and those given haloperidol (N=25). The olanzapine group showed a significant increase of glucose levels at the end of the 6-week variable-dose period (N=22). Fourteen of the 101 patients developed abnormal glucose levels (>125 mg/dl) during the trial (six with clozapine, four with olanzapine, three with risperidone, and one with haloperidol). Cholesterol levels were increased at the end of the 8-week fixed-dose period for the patients given clozapine (N=27) and those given olanzapine (N=26); cholesterol levels were also increased at the end of the 6-week variable-dose period for patients given olanzapine (N=22). CONCLUSIONS: In this prospective randomized trial, clozapine, olanzapine, and haloperidol were associated with an increase of plasma glucose level, and clozapine and olanzapine were associated with an increase in cholesterol levels. The mean changes in glucose and cholesterol levels remained within clinically normal ranges, but approximately 14% of the patients developed abnormally high glucose levels during the course of their participation in the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Reliability and validity of the positive and negative syndrome scale for schizophrenics
Kay, S. R., Opler, L. A., & Lindenmayer, J.-P. (1988) · Psychiatry Research · doi:10.1016/0165-1781(88)90038-8 · Cited by 1,007
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia
Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., & Selke, G. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.4.337 · Cited by 520
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Self-citationDiabetes mellitus in schizophrenic patients
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90054-1 · Cited by 368
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317
Melkersson, K. I., Hulting, A.-L., & Brismar, K. E. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 299
Burke, J. P., Williams, K., Gaskill, S. P., Hazuda, H. P., Haffner, S. M., & Stern, M. P. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.13.1450 · Cited by 294
Long-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0204 · Cited by 269
Olanzapine Increases Weight and Serum Triglyceride Levels
Osser, D. N., Najarian, D. M., & Dufresne, R. L. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1109 · Cited by 229
New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine Treatment
Goldstein, L. E., Sporn, J., Brown, S., Kim, H., Finkelstein, J., Gaffey, G. K., Sachs, G., & Stern, T. A. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71210-7 · Cited by 220
Lund, B. C., Perry, P. J., Brooks, J. M., & Arndt, S. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.12.1172 · Cited by 194
Antipsychotic-Induced Weight Gain and Therapeutic Response: A Differential Association
Czobor, P., Volavka, J., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00003 · Cited by 185
Self-citationClozapine and Associated Diabetes Mellitus
Popli, A. P., Konicki, P. E., Jurjus, G. J., Fuller, M. A., & Jaskiw, G. E. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0304 · Cited by 185
A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States
Buse, J. (2003) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(02)00588-7 · Cited by 176
Hyperglycemia associated with the use of atypical antipsychotics.
Lindenmayer, J., Nathan, A. M., & Smith, R. C. (2001) · PubMed · Cited by 155
Self-citationPhenothiazines and Diabetes in Hospitalized Women
Thonnard‐Neumann, E. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.7.978 · Cited by 145
DELAYED ACTION OF INSULIN IN SCHIZOPHRENIA
Braceland, F. J., Meduna, L. J., & VAICHULIS, J. A. (1945) · American Journal of Psychiatry · doi:10.1176/ajp.102.1.108 · Cited by 129
Melkersson, K. I., Hulting, A., & Brismar, K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1112 · Cited by 125
New-onset diabetes and ketoacidosis with atypical antipsychotics
Wilson, D. R., D'Souza, L., Sarkar, N., Newton, M., & Hammond, C. M. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00331-0 · Cited by 114
Hyperglycemia Associated With Olanzapine
Fertig, M. K., Brooks, V. G., Shelton, P. S., & English, C. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1208c · Cited by 110
New-Onset Diabetes Mellitus Associated With the Initiation of Quetiapine Treatment
Sobel, M., Jaggers, E. D., & Franz, M. A. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0809f · Cited by 107
Olanzapine-Induced Glucose Dysregulation
Bettinger, T. L., Mendelson, S. C., Dorson, P. G., & Crismon, M. L. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19327 · Cited by 105
Ober, S. K., Hudak, R., & Rusterholtz, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.970 · Cited by 93
Serum triglyceride levels in patients treated with clozapine
Ghaeli, P., & Dufresne, R. L. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.17.2079 · Cited by 85
Schernthaner, G., Prager, R., PUNZENGRUBER, C., & Luger, A. (1985) · Diabetologia · doi:10.1007/bf00273860 · Cited by 84
Diabetic Ketoacidosis Associated With Risperidone Treatment?
Croarkin, P. E., Jacobs, K. M., & Bain, B. K. (2000) · Psychosomatics · doi:10.1176/appi.psy.41.4.369 · Cited by 82
Ketoacidosis as a side‐effect of clozapine: a case report
Kostakolu, A. E., Yazici, M. K., Erbas, T. A., & Guvener, N. D. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb10635.x · Cited by 78
Olanzapine-Induced Elevation of Plasma Triglyceride Levels
Sheitman, B., BIRD, P. M., Binz, W., AKINLI, L., & SANCHEZ, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1471-a · Cited by 69
Self-citationPeripheral glucose metabolism in human hyperprolactinaemia
Foss, M. C., de Paula, F. J. A., Paccola, G. M. G. F., & Piccinato, C. E. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb00541.x · Cited by 66
THE BLOOD SUGAR CURVE IN MENTAL DISEASE: II. THE SCHIZOPHRENIC (DEMENTIA PRAECOX) GROUPS
KASANIN, J. (1926) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1926.02200280022002 · Cited by 62
Glucose-insulin metabolism in chronic schizophrenia.
Brambilla, F., Guastalla, A., Guerrini, A., Riggi, F., Rovere, C., Zanoboni, A., & Zanoboni-Muciaccia, W. (1976) · PubMed · Cited by 54
New-onset diabetes mellitus associated with quetiapine.
Procyshyn, R. M., Pande, S. D., & Tse, G. (2000) · PubMed · Cited by 52
Clozapine-Induced Diabetic Ketoacidosis
Smith, H., Kenney‐Herbert, J., & Knowles, L. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/0004867900027 · Cited by 50
Glucose-insulin metabolism in chronic schizophrenia
Brambilla, F., Guastalla, A., Guerrini, A., Riggi, F., Rovere, C., Zanoboni, A., & Zanoboni-Muciaccia, W. (1975) · Progress in brain research · doi:10.1016/s0079-6123(08)63700-0 · Cited by 37
Hyperglykämie und Ketoazidose unter Olanzapin
Hayek, D. V., Hüttl, V., Reiss, J., Schweiger, H.-D., & Füeßl, H. S. (1999) · Der Nervenarzt · doi:10.1007/s001150050520 · Cited by 37
Characteristics of diabetes mellitus in schizophrenic patients.
Tabata, H., Kikuoka, M., Kikuoka, H., BESSHO, H., Hirayama, J., Hanabusa, T., Kubo, K., Momotani, Y., Sanke, T., & Nanjo, K. (1987) · PubMed · Cited by 27
Cited by
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Self-citationFreedman, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035458 · Cited by 587
Belmaker, R. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035354 · Cited by 473
Metadata
- Authors
- Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A.
- Venue
- American Journal of Psychiatry
- Published
- 2003-02-01
- Volume
- 160
- Issue
- 2
- Pages
- 290-296
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2105918612
- Cited by
- 465
- References
- 40
- FWCI
- 33.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.